Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab and golimumab combination therapy for moderately to severely active ulcerative colitis
2023-504743-13-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 37
01
Overview
Phase 2, randomised, double-blind trial of guselkumab and golimumab in autoimmune colitis (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical remission at Week 48 compared with each monotherapy. Planned start Nov 2022; status: authorised.
02
Drugs
guselkumabgolimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-504743-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504743-13-00.